Possible role of FDG-PET in the evaluation of urologic malignancies

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1655-1660

  Bender, Hans ^a   Schomburg, A ^a   Albers, P ^a   Ruhlmann, J ^a   Biersack, H J ^b  

^a UNIVERSITY OF BONN   (Germany)

^b PET Center ^*

Author keywords

Bladder cancer; Fluoro deoxyglucose; Kidney cancer; Positron emission tomography; Prostate cancer; Testicular cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MORPHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TERATOMA; TESTIS CARCINOMA; TISSUE METABOLISM; URINARY TRACT CANCER;

CARCINOMA, RENAL CELL; DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 0031005684     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Shields AF, Graham MM, Spence AM: The role of PET imaging in clinical oncology: A current status report. In: Ann Rev Nucl Med, eds. Freeman LM, Raven Press, New York 1995.
2. Clavo A, Brown RS, Wahl RL: Hypoxia-induced increases in tumor FDG accumulation are associated with increased Glut-1 expression and increased membrane glucose transport. J Nucl Med 36: 62P, 1995.
3. Perez CA, Fair WR, Ihde DC: Carcinoma of the Prostate. In: Cancer, Principles and practice of oncology, 3rd edition; eds. DeVita VT Jr, Hellman S, Rosenberg SA, J.B. Lippincott Company, Philadelphia 1989.
4. Bares R, Effert P, Handt S, Altehoefer C, Cremerius U, Wittstock D, Boecking A, Mittermayer C, Jakse G, Buell U: Metabolic classification of untreated prostate cancer by use of FDG-PET. J Nucl Med 35: 230P, 1994
5. Laubenbacher C, Hofer C, Avril N, Block T, Ziegler S, Herz M, Kruschke C, Hartung R, Schwaiger M: F-18 FDG PET for differentiation of local recurrent prostatic cancer and scar. J Nucl Med 36: 198P, 1995.
6. Reinhardt M, Mueller-Matheis V, Larisch R, Vosberg R, Ackermann R, Mueller-Gaertner HW: Time activity analysis improves specificity of FDG-PET in staging of pelvic lymph node metastases. Eur J Nucl Med 22: 803, 1995
7. Shreve P, Gross MD, Wahl RL: Detection of prostate cancer metastases with FDG. J Nucl Med 36: 189P, 1995.
8. Hon CK, Rosen PJ, Belldegrun A, Moon DH, Maddahi J, Phelps ME: Quantitative and whole body FDG PET in the evaluation of suramine therapy in patients with metastatic prostate cancer. J Nucl Med 37: 267P, 1996
9. Yen SDJ, Imbriaco M, Garza D, Kalaigian H, Reddy D, Zhang JJ, Horowitz S, Finn R, Goldsmith SJ, Scher H, Larson SM: Twenty percent of hormone resistant prostate cancer are detected by PET-FDG whole body scanning. J Nucl Med 36: 198P, 1995.
10. Einhorn LH, Crawford ED, Shipley WU, Loehrer PJ, Williams SD: Cancer of the Testes. In: Cancer. Principles and practice of oncology, 3rd edition: eds. DeVita VT Jr, Hellman S, Rosenberg SA, J.B. Lippincott Company, Philadelphia 1989.
11. Dohmen BM, Bares R, Gromius R, Harms W, Kamps H, Boeckmann W, Jakse G, Buell U: Improved staging of germ cell cancer after chemotherapy by FDG-positron-emission-tomography (PET), Eur J Nucl Med 22: 804, 1995.
12. Wilson CB, Young HE, Ott RJ, Flower MA, Cronin BF, Pratt BE, McCready VR, Horwich A: Imaging metastatic testicular germ cell tumours with F18-FDG positron emission tomography: prospects for detection and management. Eu J Nucl Med 22: 508-513, 1995
13. Harms W, Bares R, Gromius R, Kamps H, Schulz G, Boeckmann W, Jakse G, Buell U: FDG-PET zur Vitalitaetsdiagnostik metastasierter Hodentumoren nach Chemotherapie. Nucl Med 35: V27, 1995.
14. Harms W, Bares R, Kamps H, Gronimus R, Boeckmann W, Jakse G, Buell U: Therapy control of metastatic testicular carcinoma with F18-DOG PET. J Nucl Med 36: 198P, 1995.
15. Laubenbacher C, Block T, Avril N, Hofer C, Ziegler S, Herz M, Kruschke C, Hartung R, Schwaiger M: Lymph node status in patients with testicular cancer: Assessment by F-18 FDG PET. Eur J Nucl Med 22: 888, 1995.
16. Reinhardt M, Mueller-Matheis V, Vosberg H, Ackermann R, Mueller-Gaeertner H-W: Staging of lymph nodes in testicular cancer by FDG-PET: Eur J Nucl Med 22: 804, 1995.
17. Bender H, Schomburg A, Albers P, Palmedo H, Menzel C, Klemm E, Gruenwald F, Ruhlmann J, Mueller SC, Biersack HJ: Grenzen von Ganzkoerper FDG-PET von Hoden-Tumoren. Nucl-Med, 1996.
18. Nuutinen J, Leskinen S, Elomaa I, Salminen E, Haapaanta U, Ruotsalainen U, Wegelius U, Minn H: FDG-PET imaging of residual testicular cancer after chemotherapy. J Nucl Med 37: 256P, 1996.
19. Richie JP, Shipley WU, Yagoda A: Cancer of the bladder. In: Cancer, Principles and practice of oncology, 3rd edition; eds. DeVita VT Jr, Hcllman S, Rosenberg SA, J.B. Lippincott Company, Philadelphia 1989.
20. Skinner DG, Tift JP, Kaufmann JJ: High-dose short-course preoperative radiation therapy and immediate single stage radical cystectomy with pelvic node dissection in the management of bladder cancer. J Urol 127: 671-678, 1982.
21. See WA, Fuller JR: Staging of advanced bladder cancer. Current concepts and pitfalls. Urol Clin North Am 19: 663-83, 1992.
22. Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE: Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results. Urol Arch 34: 138-142, 1995.
23. Kocher F, Bachor R, Stollfuß JC, Hautmann R, Reske SN: Positron-emission-tomography of urinary bladder carcinoma. Eur J Nucl Med 20: 888, 1995.
24. Kocher F, Geimmel S, Hauptmann R, Reske SN: Preoperative lymph node staging in patients with kidney and urinary bladder neoplasms. J Nucl Med 35: 223P, 1994.
25. Kosuda S, Grossman HB, Kison PV, Wahl RL: Preliminary FDG-PET study in patients with bladder cancer. J Nucl Med 37: 260P, 1996.
26. Linehan WM, Shipley WU, Longo DL: Cancer of the kidney and ureter. In: Cancer, Principles and practice of oncology, 3rd edition; eds. DeVita VT Jr. Hellman S, Rosenberg SA, J.B. Lippincott Company, Philadelphia 1989.
27. Hoh CK, Figlin RA, Belldegrum A, Moon DH, Franklin J, Phelps ME, Maddahi J: Evaluation of renal cell carcinoma with whole body FGD PET. J Nucl Med 37: 141P 1996.
28. Miyauchi T, Brown RS, Grossman HB, Wojno K, Wahl RL. Correlation between visualization of primary renal cancer by FDG-PET and histopthological findings. J Nucl Med 37: 64P, 1996.